BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mahmoudi H, Ebrahimi E, Daneshpazhooh M, Balighi K, Mirzazadeh A, Elikaei Behjati S, Tavakolpour S. Single-nucleotide polymorphisms associated with pemphigus vulgaris: Potent markers for better treatment and personalized medicine. Int J Immunogenet 2020;47:41-9. [PMID: 31342641 DOI: 10.1111/iji.12451] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Mahmoudi H, Tavakolpour S, Balighi K, Farid AS, Nili A, Jan D, Daneshpazhooh M. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration. Dermatol Ther 2021;34:e14633. [PMID: 33280226 DOI: 10.1111/dth.14633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Abida O, Bahloul E, Ben Jmaa M, Sellami K, Zouidi F, Fakhfakh R, Mahfoudh N, Turki H, Masmoudi H. Chromosome 2q33genetic polymorphisms in Tunisian endemic pemphigus foliaceus. Mol Genet Genomic Med 2020;8:e1476. [PMID: 32875738 DOI: 10.1002/mgg3.1476] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Di Lernia V, Casanova DM, Goldust M, Ricci C. Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment. Dermatol Pract Concept 2020;10:e2020050. [PMID: 32642305 DOI: 10.5826/dpc.1003a50] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
4 Tavakolpour S, Mahmoudi H, Karami F, Elikaei Behjati S, Balighi K, Abbasi M, Salehi Farid A, Masoudi J, Balali M, Daneshpazhooh M, Modarressi MH. Investigating expression pattern of eight immune‐related genes in pemphigus patients compared with the healthy controls and after rituximab therapy: Potential roles of CTLA4 and FCGR3A genes expression in outcomes of rituximab therapy. Dermatologic Therapy 2020;33. [DOI: 10.1111/dth.14380] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Ghaedi F, Etesami I, Aryanian Z, Kalantari Y, Goodarzi A, Teymourpour A, Tavakolpour S, Mahmoudi H, Daneshpazhooh M. Drug-induced pemphigus: A systematic review of 170 patients. Int Immunopharmacol 2021;92:107299. [PMID: 33418246 DOI: 10.1016/j.intimp.2020.107299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Cheng Y, Li X, Dai Y, Dong Y, Yang X, Wang J. Identification of an immune-related risk signature and nomogram predicting the overall survival in patients with endometrial cancer. J Gynecol Oncol 2021;32:e30. [PMID: 33559412 DOI: 10.3802/jgo.2021.32.e30] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Shahbazian P, Izad M, Daneshpazhooh M, Mortazavi H, Salehi Z, Behruzifar S, Tavakolpour S, Azizpour A. Decreased Serum Levels of Interleukin-4 and Interleukin-21 in New Pemphigus Vulgaris Patients, but Not Chronic Patients With Inactive Disease Compared to Healthy Controls. Dermatol Pract Concept 2021;11:e2021035. [PMID: 33954018 DOI: 10.5826/dpc.1102a35] [Reference Citation Analysis]
8 Gouda NS, Fawzy MS, Toraih EA. Impact of cytotoxic T-lymphocyte-associated protein 4 codon 17 variant and expression on vitiligo risk. J Clin Lab Anal 2021;35:e23777. [PMID: 33932254 DOI: 10.1002/jcla.23777] [Reference Citation Analysis]